Medtronic

URGENT FIELD SAFETY NOTICE

MiniMed™ Paradigm™, MiniMed™ 600 series, and MiniMed™ 700 series insulin pump systems

Pump Placement with Respect to Infusion Site

Notification

Products impacted:

Insulin Pump	Model/CFN Number
Paradigm™	MMT-715, MMT-722, MMT-754
MiniMed™ 640G Insulin Pump	MMT-1711, MMT-1751
MiniMed™ 670G Insulin Pump	MMT-1762, MMT-1782
MiniMed™ 740G Insulin Pump	MMT-1811, MMT-1861
MiniMed™ 780G Insulin Pump	MMT-1885, MMT-1895

Please visit https://www.medtronic-diabetes.com/da-DK/resources for affected user guide versions.

February 2026

Medtronic reference: FA1514
EU Manufacturer Single Registration Number (SRN): US-MF-000023100

Dear Healthcare Professional,

You're receiving this letter because our records indicate that one or more people with diabetes under your care have a MiniMed™ Paradigm™, MiniMed™ 600 series and/or MiniMed™ 700 series insulin pump. We are writing to request that you share with people with diabetes under your care who have received impacted devices the enclosed letter that informs them that there may be slight variability in the amount of insulin delivered when their pump is worn at distances above or below the location of their infusion set and provides guidance on how to position their pump.

We ask you to please carefully review the information below and in the enclosed patient letter and acknowledge that you have received this notification. Thank you for your patience as we work to continuously improve the experience of people with diabetes under your care; their safety is our top priority.

Medtronic

Medtronic asks that you inform people with diabetes under your care who are using a MiniMed™ Paradigm™, MiniMed™ 600 series, and/or MiniMed™ 700 series pump using the enclosed letter.

Your Required Actions:

- Send existing people with diabetes under your care the Urgent Field Safety Notice containing the required steps for them to take.
- Complete and return the attached Customer Acknowledgement Form to acknowledge that you have reviewed and understood this notification and have taken all required actions.

The Competent Authority of your country has been notified of this action.

At Medtronic, safety is our top priority, and we are committed to delivering safe and effective therapies. We appreciate your time and attention in reading this important notification and in taking the time to notify affected insulin pump users in your care. We apologize for any inconvenience. For more information and the latest updates, please reach out to your Medtronic contact. In the meantime, if your patient needs support during this time, please have them contact the Medtronic Helpline.

Sincerely,

Federico Gavioli
Sr Vice President Diabetes EMEA & Americas
Medtronic Diabetes

Ohad Cohen M.D.
Global Sr. Medical Affairs Director
Medtronic Diabetes

Enclosure: Pump User Letter